Lianyungang Daily's A2 Page Report, Hansoh Pharma: Building a Domestic Leader in Innovative Drugs, dated October 24
Link to the report: http://epaper.lyg01.net/lygrb/html/2016-10/24/content_201552.htm?div=-1
Original text:
Recently, under the guidance of China Pharmaceutical University, Modern Chinese Mevelopment Research Center, and Chongqing Economic and Information Technology Committee, the 2016 China Pharmaceutical · R&D Innovation Summit and the Release Conference of Top 100 Pharmaceutical Enterprises in R&D Strength, hosted by Medicine Intellectual Elite Club and organized by YAOZH.COM, were grandly held in Chongqing, at which the general ranking and four sub-rankings of "2016 China Drug R&D Comprehensive Strength Ranking" were released. Hansoh Pharma was ranked third in China Chemical Drug R&D Strength Ranking. The management of Hansoh Pharma said that the company attaches great importance to R&D investment. Its annual expenses for product R&D show a year-on-year rising trend, which effectively ensures the continuous upgrading of the R&D system and R&D capability. Up to now, Hansoh Pharma's drug research covers the six fields of anti-tumor, psychiatric, diabetes, gastrointestinal, anti-infection and cardiovascular, and it is the domestic leader in anti-tumor, psychiatric and endocrine fields, occupying a dominant position in the market.
According to the management of Hansoh Pharma, the company has so far established and improved R&D platforms for chemical drugs, biological drugs, new preparations, quality research and pilot scale-up, placing high emphasis on the R&D of innovative drugs. It has also set up three R&D centers in the United States, Shanghai and Lianyungang headquarters, which are enterprise technology centers and central-local joint engineering research centers recognized by the state and consist of national postdoctoral research stations, provincial academician workstations and biopharmaceutical high-tech research laboratories.
Since the launch of the 11th Five-Year Plan, Hansoh Pharma has successively undertaken a number of major projects including the National Major New Drug Innovation Initiative, 863 Program and National Innovation Fund. A large number of national Class 1.1 new drugs with independent intellectual property rights have entered clinical research, and some products will be put on the market in recent years. Ranked among domestic top three in the same industry for its independent innovation capacity, Hansoh Pharma was named a "National Technology Innovation Demonstration Enterprise" in 2012.
Moreover, Hansoh Pharma's factories have internationally advanced manufacturing and testing equipment and lean manufacturing processes, and have established a strict quality management system and quality standards in line with international standards. The APIs and preparations of its leading products have passed the US FDA certification and have been sold to Europe, the US, Japan and other international mainstream markets.
